Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Isoniazid preventive therapy completion and factors associated with non-completion among patients on antiretroviral therapy at Kisenyi Health Centre IV, Kampala, Uganda

View ORCID ProfileIan Amanya, View ORCID ProfileMichael Muhoozi, Dickson Aruhomukama, Anthony Ssebagereka, Richard Mugambe
doi: https://doi.org/10.1101/2022.11.03.22281894
Ian Amanya
1Department of Epidemiology and Biostatistics, School of Public Health, College of Health Sciences, Makerere University
5Brainmann Analytics, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ian Amanya
  • For correspondence: ianamanya24@gmail.com
Michael Muhoozi
1Department of Epidemiology and Biostatistics, School of Public Health, College of Health Sciences, Makerere University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael Muhoozi
Dickson Aruhomukama
2Department of Medical Microbiology, School of Biomedical Sciences, College of Health Sciences, Makerere University
3Department of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University
5Brainmann Analytics, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Ssebagereka
1Department of Epidemiology and Biostatistics, School of Public Health, College of Health Sciences, Makerere University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Mugambe
4Department of Disease Control and Environmental Health, School of Public Health, College of Health Sciences, Makerere University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Isoniazid preventive therapy (IPT) is given to HIV patients to reduce the risk of active tuberculosis (TB). However, treatment completion remains sub-optimal among those that are initiated. This study aimed to determine the completion level of IPT and the factors associated with non-completion among people on antiretroviral therapy (ART) at Kisenyi Health Center IV in Kampala, Uganda.

Methods A facility-based retrospective cohort study utilizing routinely collected data of 341 randomly selected HIV patients initiated on IPT was conducted. Data extracted from the registers were used to determine the IPT completion. Modified Poisson regression with robust error variances was used to determine the associated factors of IPT non-completion while in-depth interviews were conducted to explore barriers to IPT completion from the patient’s perspective.

Results A total of 341 patients who started on isoniazid (INH) were retrospectively followed up, with 69% (236/341) being female. Overall IPT completion was at 83%. Multivariable analysis revealed the prevalence of IPT non-completion among males was 2.24 times the prevalence among females [aPR 2.24, 95% CI: 1.40-3.58]. The prevalence of IPT non-completion among patients with a non-suppressed HIV viral load was 3.00 times the prevalence among those with a suppressed HIV viral load [aPR 3.00, 95% CI: 1.44-6.65]. Patients who were married/cohabiting had a 69% lower prevalence of IPT non-completion compared to those who were single [aPR 0.31, 95% CI: 0.17-0.55]. Lack of IPT-related health education, pill burden, distance to the health facility, and patient relocation were reported as the barriers to IPT completion.

Conclusion IPT completion was found to be at 83% among the cohort studied. However, lower completion levels persist among males and HIV virally non-suppressed patients. Lack of IPT-related health education, pill burden, distance to the health facility, and patient relocation were reported as the barriers to IPT completion. Interventions that target these groups of people need to be intensified.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors received no specific funding for this work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval for the study was sought and granted by Makerere University School of Public Health Higher Degrees, Research and Ethics Committee.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data underlying the results presented in the study are available from https://drive.google.com/file/d/1-VCy-JfMOuDt1d24e7kOdO_iBjHNWY-2/view?usp=sharing

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted November 05, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Isoniazid preventive therapy completion and factors associated with non-completion among patients on antiretroviral therapy at Kisenyi Health Centre IV, Kampala, Uganda
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Isoniazid preventive therapy completion and factors associated with non-completion among patients on antiretroviral therapy at Kisenyi Health Centre IV, Kampala, Uganda
Ian Amanya, Michael Muhoozi, Dickson Aruhomukama, Anthony Ssebagereka, Richard Mugambe
medRxiv 2022.11.03.22281894; doi: https://doi.org/10.1101/2022.11.03.22281894
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Isoniazid preventive therapy completion and factors associated with non-completion among patients on antiretroviral therapy at Kisenyi Health Centre IV, Kampala, Uganda
Ian Amanya, Michael Muhoozi, Dickson Aruhomukama, Anthony Ssebagereka, Richard Mugambe
medRxiv 2022.11.03.22281894; doi: https://doi.org/10.1101/2022.11.03.22281894

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • HIV/AIDS
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1094)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9760)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2304)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1554)
  • Health Policy (734)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (502)
  • Infectious Diseases (except HIV/AIDS) (11637)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2140)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1173)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (309)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (266)
  • Psychiatry and Clinical Psychology (2176)
  • Public and Global Health (4649)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (456)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)